(1) Gobbini E (2) Hubert M (3) Doffin AC (4) Eberhardt A (5) Hermet L (6) Li D (7) Duplouye P (8) Ghamry-Barrin S (9) Berthet J (10) Benboubker V (11) Grimont M (12) Sakref C (13) Perrot J (14) Tondeur G (15) Harou O (16) Lopez J (17) Dubois B (18) Dalle S (19) Caux C (20) Caramel J (21) Valladeau-Guilemond J
Gobbini and Hubert et al. performed multiplexed immunofluorescence combined with computational image analyses of DC localization within skin lesions from patients with advanced melanoma treated with ICI. Although pDCs were six times more prevalent than the equally represented cDC1s and mature LAMP3+ DCs in the TME, all DC subsets were associated with a positive response to ICI. cDC1s were dispersed, whereas pDCs and LAMP3+ DCs were homotypically aggregated in dense areas in the TME. The interaction between CD8+ T cells and cDC1s, but not other DC subsets, was strongly associated with patients’ positive responses to ICI.
Contributed by Paula Hochman
(1) Gobbini E (2) Hubert M (3) Doffin AC (4) Eberhardt A (5) Hermet L (6) Li D (7) Duplouye P (8) Ghamry-Barrin S (9) Berthet J (10) Benboubker V (11) Grimont M (12) Sakref C (13) Perrot J (14) Tondeur G (15) Harou O (16) Lopez J (17) Dubois B (18) Dalle S (19) Caux C (20) Caramel J (21) Valladeau-Guilemond J
Gobbini and Hubert et al. performed multiplexed immunofluorescence combined with computational image analyses of DC localization within skin lesions from patients with advanced melanoma treated with ICI. Although pDCs were six times more prevalent than the equally represented cDC1s and mature LAMP3+ DCs in the TME, all DC subsets were associated with a positive response to ICI. cDC1s were dispersed, whereas pDCs and LAMP3+ DCs were homotypically aggregated in dense areas in the TME. The interaction between CD8+ T cells and cDC1s, but not other DC subsets, was strongly associated with patients’ positive responses to ICI.
Contributed by Paula Hochman
ABSTRACT: Dendritic cells (DCs) are promising targets for cancer immunotherapies because of their central role in the initiation and control of immune responses. The rare cDC1 population is of particular interest because of its remarkable ability to cross-present antigens (Ag) to CD8+ T cells, to promote Th1 cell polarization and NK cell activation and recruitment. However, the spatial organization and specific functions of cDC1s in response to immunotherapy remain to be clearly characterized in human tumors. Here, we implemented a multiplexed immunofluorescence analysis pipeline coupled with computational image analysis to determine the spatial organization of the cDC1 subset in a cohort of skin lesions from advanced melanoma patients treated with immune checkpoint inhibitors (ICI). For this, we performed a whole-slide image analysis of cDC1 infiltration and distribution as well as their spatial interactions with key immune partners such as CD8+ T cells and pDC according to the response of patients to ICI. We also analyzed LAMP3+-DC, which correspond to a mature subset of tumor-infiltrating DCs. Distance and cell network analyses demonstrated that cDC1s exhibited a scattered distribution compared to tumor-infiltrating pDCs and LAMP3+-DCs, which were preferentially organized in dense areas with high homotypic connections. Interestingly, the proximity and interactions between CD8+ T cells and cDC1s were positively associated with the response to ICI. In conclusion, our study unravels the complex spatial organization of cDC1s and their interactions with CD8+ T cells in melanoma patient lesions, shedding light on their pivotal role in shaping the response to ICI.
Author Info: (1) Institute Curie, PARIS, France. (2) Centre de Recherche en Cancérologie de Lyon, Lyon, France. (3) Cancer Center of Lyon, LYON, France. (4) Cancer Center of Lyon, LYON, France.

Author Info: (1) Institute Curie, PARIS, France. (2) Centre de Recherche en Cancérologie de Lyon, Lyon, France. (3) Cancer Center of Lyon, LYON, France. (4) Cancer Center of Lyon, LYON, France. (5) Cancer Center of Lyon, LYON, France. (6) Cancer Center of Lyon, LYON, France. (7) Cancer Center of Lyon, Lyon, France. (8) CIMI-Paris, SU UMRS CR7, Inserm UMRS 1135, AP-HP, Paris, France. (9) Centre de Recherche en Cancérologie de Lyon, Lyon, France. (10) Cancer Center of Lyon, Lyon, France. (11) Cancer Center of Lyon, Lyon, France. (12) Cancer Center of Lyon, LYON, France. (13) Centre Hospitalier Lyon Sud, France. (14) Hospices Civils de Lyon, France. (15) Hospices Civils de Lyon, France. (16) Université de Lyon, Lyon, France. (17) CRCL, UMR INSERM 1052, CNRS 5286, Lyon, France. (18) Claude Bernard Lyon University, Lyon, France. (19) Centre de Recherche en Cancérologie de Lyon, Lyon, France. (20) Cancer Center of Lyon, Lyon, France. (21) Cancer Center of Lyon, LYON, France.

Citation: Cancer Immunol Res 2025 Jan 7 Epub01/07/2025